An Open Label Study to Evaluate DPCP Ointment for the Treatment of Alopecia Areata
The purpose of the study is two-fold. First, we will see whether treating alopecia areata with a ointment containing DPCP is safe and causes hair to regrow. Second, we will take blood and scalp biopsy samples and analyze them for biomarkers. The biomarkers in this study are molecules related to DNA that tell us whether certain genes are turned on or off. Those markers may help us predict whether or not patients respond to this type of treatment. The testing for biomarkers will also help us to better understand what causes alopecia areata. This study requires you to make forty-two (42) visits to the study site over a course of approximately four (4) months.
• diagnosis of extensive alopecia areata
• women of childbearing age must agree to use an acceptable, highly effective method of birth control to prevent pregnancy
• women who are pregnant or breast feeding
• current controlled or uncontrolled infection of any type
• systemic therapy for cancer within the past five years except for adequately treated Squamous Cell Carcinoma (SCC) or Basal Cell Carcinoma (BCC) of the skin
• additional medical conditions, treatments for alopecia areata, or mental health diagnosis (study staff will review)
Drug: Diphenylcyclopropenone (DPCP) Ointment
Dermatology (Skin, Hair & Nails)
Alopecia Areata